Atlas Trials

Refractory Ewing Sarcoma

13 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Ewing Sarcoma

RecordFirmDate
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (NCT05071209)National Cancer Institute (NCI)2021-12-22
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119)Children's Oncology Group2021-11-08
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)St. Jude Children's Research Hospital2021-06-09
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888)National Cancer Institute (NCI)2021-05-03
Cabozantinib With Topotecan-Cyclophosphamide (NCT04661852)Dana-Farber Cancer Institute2020-12-23
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774)National Cancer Institute (NCI)2020-10-13
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994)National Cancer Institute (NCI)2018-11-14
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250)National Cancer Institute (NCI)2018-08-13
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)National Cancer Institute (NCI)2017-07-31
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592)National Cancer Institute (NCI)2017-05-18
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma (NCT02546544)University of Oxford2014-03-01

Track Refractory Ewing Sarcoma automatically

Every clearance here is in the API, with alerts when new ones post.